Overview

AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

Status:
Recruiting

Trial end date:
2028-10-01

Target enrollment:
0

Participant gender:
All

Summary

There has no evidence for the anticoagulation in patients who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year. However, anticoagulation can increase the risk of bleeding, the study evaluating the role of oral anticoagulation is needed in this patients. This study will compare the efficacy and safety of non-vitamin K anticoagulants (apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Yonsei University

Treatments:

Apixaban

Criteria

Inclusion Criteria:

1. no recurrence of atrial fibrillation one year after catheter ablation of atrial
fibrillation

2. CHA2DS2-VASc score >=1 (male) or >=2 (female)

3. age: 19 to 80 years

4. non-valvular atrial fibrillation

5. those who consent the study.

6. those who can be followed after enrollment

Exclusion Criteria:

1. Severe liver or kidney dysfunction

2. Thyroid dysfunction

3. Pregnant or breastfeeding women

4. Malignant tumors that have not been completely cured

5. Severe structural heart disease

6. Predicted survival is less than 12 months

7. Patients who do not understand the content of the study or disagree with it